Skip to main content
STVN
NYSE Industrial Applications And Services

Stevanato Q3 Revenue Up 8% to €326.1M; FY26 Guidance Held, 2027 GLP-1 Growth Curbed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.1
Mkt Cap
$3.849B
52W Low
$12.89
52W High
$27
52W Position info
9.4% above low
Off High info
48% below high
Rel. Volume info
11× avg
Market data snapshot near publication time

STVN is trading near its 52-week low of $12.89 (9.4% above the low) on elevated volume (11× avg).

Summary

Stevanato delivered 8% organic Q3 revenue growth to €326.1 million with adjusted EBITDA margin up 150 basis points to 27.2%, held its full-year 2026 guidance, but flagged lower-than-expected GLP-1 volumes that will temper growth in 2027.


Key Events · Earnings and Guidance · STVN

  • Q3 Revenue Grows 8% Organically

    Revenue rose 8% to €326.1 million, entirely organic, with high-value solutions at 46% of total revenue.

  • Margins Expand, EPS Up 15%

    Adjusted EBITDA margin rose 150 basis points to 27.2% on €88.8 million of adjusted EBITDA; diluted EPS grew 15% to €0.15 and adjusted diluted EPS 14% to €0.16.

  • Segment Split: BDS Up, Engineering Down

    Biopharmaceutical and Diagnostic Solutions revenue grew 11% organically to €294.0 million, offsetting a 12% decline in Engineering revenue to €32.0 million.

  • FY26 Guidance Maintained

    Full-year 2026 guidance unchanged: revenue €1.260-1.280 billion, adjusted EBITDA €335.0-345.2 million, adjusted diluted EPS €0.60-0.62.


Analysis · STVN · Industrial Applications And Services

Third-quarter results met management's expectations: organic revenue grew 8% to €326.1 million, adjusted EBITDA margin rose 150 basis points to 27.2%, and adjusted diluted EPS came in at €0.16 versus €0.14 a year ago. The forward view matters more. The CEO now expects lower GLP-1 volumes and revenue than previously assumed, which will temporarily moderate 2027 growth, though management says it has already backfilled much of the gap and still sees low-single-digit growth next year. Full-year 2026 guidance is unchanged at €1.260-1.280 billion of revenue and €0.60-0.62 of adjusted diluted EPS. The mix is uneven: Biopharmaceutical and Diagnostic Solutions grew 11% organically while the Engineering segment fell 12%, and GLP-1 therapies were roughly 17-18% of total revenue in the quarter.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, STVN was trading at $14.10 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $12.89 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STVN - Latest Insights

STVN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.38
Real-time Price: $15.65 info
Change: +$2.27 (+17%) info
Market Cap: $4.273B info
STVN
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $15.65 info
Change: +$1.49 (+11%) info
Market Cap: $4.273B info
STVN
Nov 03, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.46
Real-time Price: $15.65 info
Change: +$1.19 (+8%) info
Market Cap: $4.273B info
STVN
Nov 03, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.74
Real-time Price: $15.65 info
Change: -$4.09 (-21%) info
Market Cap: $4.273B info
STVN
Aug 06, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.30
Real-time Price: $15.65 info
Change: -$4.65 (-23%) info
Market Cap: $4.273B info